A senior University of Minnesota scientist said it is "devastating" that a colleague might have doctored images to prop up research, but she defended the authenticity of her groundbreaking work on the origins of Alzheimer's disease.
Dr. Karen Ashe declined to comment about a U investigation into the veracity of studies led by Sylvain Lesn, a neuroscientist she hired and a rising star in the field of Alzheimer's research. However, she criticized an article in Science magazine that raised concerns this week about Lesn, because she said it confused and exaggerated the effect the U's work had on downstream drug development to treat Alzheimer's-related dementia.
"Having worked for decades to understand the cause of Alzheimer disease, so that better treatments can be found for patients, it is devastating to discover that a co-worker may have misled me and the scientific community through the doctoring of images," Ashe said in an e-mail Friday morning. "It is, however, additionally distressing to find that a major scientific journal has flagrantly misrepresented the implications of my work."
Questions have surfaced about as many as 10 papers written by Lesn, and often coauthored by Ashe and other U scientists, and whether they used manipulated or duplicated images to inflate the role of a protein in the onset of Alzheimer's.
The Science article detailed efforts by Dr. Matthew Schrag, an Alzheimer's researcher in Tennessee, who colorized and magnified images from Lesn's studies in ways that revealed questions about whether they were doctored or copied. Expert consultants agreed in the article that some of the images in the U studies appeared manipulated in ways that elevated the importance of a protein called A*56.
Many of the images were of Western blot tests showing that A*56, also called amyloid beta star 56, was more prevalent in mice that were older and showed signs of memory loss.
The U studies have been so influential on the course of Alzheimer's research over the past two decades that any evidence of manipulation or false study results could fundamentally shift thinking on the causes of the disease and dementia. The investigation also implicates two successful researchers on a key measure by which they are judged: their ability to pull in federal grants.
Lesn was a named recipient of $774,000 in National Institutes of Health grants specifically involving A*56 from 2008 through 2012. He subsequently received more than $7 million in additional NIH grants related to the origins of Alzheimer's.
Lesn, who did not reply to an e-mail asking for comment, came to the U in 2002 as a postdoctoral research associate after earning his doctorate at the University of Caen Normandy. He took charge of his own U lab by 2009 and became associate director of graduate studies in the neuroscience program in 2020. He was the first- or last-named author on all of the disputed studies, meaning he either instigated the research or was the senior scientist overseeing the work.
Ashe said there are two classes of A proteins, which she refers to as Abeta, and that her efforts have focused on one while drugmakers have unsuccessfully targeted the other with potential Alzheimer's treatments. As a result, she said it was unfair of the Science article even as it raised concerns about research improprieties to pin an entire industry's lack of progress on the scrutinized U research.
"It is this latter form that drug developers have repeatedly but unsuccessfully targeted," she said. "There have been no clinical trials targeting the type 1 form of Abeta, the form which my research has suggested is more relevant to dementia. [The article] has erroneously conflated the two forms of Abeta."
The scientific journal Nature is reviewing a 2006 study led by Lesn regarding the existence and role of A*56 and urging people to use it cautiously for now. Concerns emerged in part because researchers at other institutions struggled to replicate the results.
Two other 2012 and 2013 papers were corrected earlier this year, with U researchers acknowledging errant images but stating that they didn't affect the overall conclusions. However, Schrag said he has concerns the corrected images also were manipulated.
"I think those corrected images are quite problematic," he said.
Beneath the research controversy is a fundamental search and debate over the causes of Alzheimer's and related dementia. One theory is that certain Abeta proteins result in the development of amyloid plaques, which clog up space between nerve cells in the brain and inhibit memory and cognition. Another is that tau proteins clump inside the brain's thinking cells and disrupt them.
Ashe's research has explored both possibilities. Since 1986, she has been a named recipient of more than $28 million in NIH grants, making her one of the most productive researchers in U history.
Complicated legacy
Despite a remarkable history of life-saving inventions and surgical accomplishments, the U also has a legacy of research stars being implicated in scandals.
The late Dr. S. Charles Schulz stepped down as U psychiatry chair in 2015 amid claims by a grieving family that their son, who died by suicide, was coercively recruited into a schizophrenia drug trial.
Duplicated images and errors forced the correction of a 2002 Nature study, led by Dr. Catherine Verfaillie, claiming that certain adult stem cells possessed flexible abilities to grow and develop other cell types.
The late Dr. John Najarian was a pioneer in organ transplantation who elevated the U's global profile, but he faced federal sanctions in the 1990s related to illicit sales of an experimental anti-rejection medication that improved transplant outcomes.
A U investigation of Lesn's work will follow its standard policy of research misconduct allegations, according to a statement from the medical school.
Read more from the original source:
University of Minnesota scientist responds to fraud allegations in Alzheimer's research - Star Tribune
- Stem cell treatment after spinal cord injury: The next steps - Mayo Clinic - December 18th, 2022
- A CRISPR Alternative for Correcting Mutations That Sensitize Cells to DNA Damage - The Scientist - October 13th, 2022
- The Switch to Regenerative Medicine - Dermatology Times - October 13th, 2022
- A history of blood cancer treatment - - pharmaphorum - September 16th, 2022
- What Are Zombie Cells? Here's How They Impact Aging - Prevention Magazine - September 8th, 2022
- ThreeSixty Journalism: Be The Match works to build equity in access to bone marrow and cord blood transplants - St. Paul Pioneer Press - September 8th, 2022
- Zhang and colleagues win an $11.2 million NIH program project grant (PPG) - News - University of Alabama at Birmingham - August 22nd, 2022
- Kyle Vining: Appointment to Faculty of Penn Dental Medicine and Penn School of Engineering and Applied Science - University of Pennsylvania - August 22nd, 2022
- Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201 - Business Wire - August 14th, 2022
- Engineers develop new tool that will allow for more personalized cell therapies - UMN News - July 27th, 2022
- Accelerating Transformational Research into Cell Transplantation for Patients with Type 1 Diabetes - UCSF - July 27th, 2022
- TC BioPharm Announces Formation of Scientific Advisory Board with Renowned Cell Therapy Experts - GuruFocus.com - July 11th, 2022
- Witt Wolfpack: Family works out fundraising and awareness after La Jollan's ALS diagnosis - La Jolla Light - July 11th, 2022
- Pluripotent stem cellderived NK cells with high-affinity noncleavable ... - July 3rd, 2022
- Life-saving lecture: Auburn student uses lessons from class to help discover father's brain tumor - Office of Communications and Marketing - June 22nd, 2022
- Bluebird's future in balance as FDA weighs gene therapy approvals - BioPharma Dive - June 13th, 2022
- Be the Match is looking for more ethnically diverse donors to help patients with blood cancers and diseases - KARE11.com - June 4th, 2022
- Minnesota woman reunites with teenager she saved through Be The Match transplant - KSTP - April 19th, 2022
- Induced Pluripotent Stem Cells and Their Potential for ... - November 22nd, 2021
- Cells or drugs? The race to regenerate the heart - Scientific American - November 8th, 2021
- Four-year-old with rare disease finally gets historic gene therapy treatment - KARE11.com - October 5th, 2021
- Caribou Biosciences Appoints Biotechnology Industry Veteran Ran Zheng to its Board of Directors - Stockhouse - October 5th, 2021
- EDITORIAL: The need is vast. Consider becoming an organ donor. - Yahoo News - August 18th, 2021
- Our View: The need is vast. Consider becoming an organ donor. - PostBulletin.com - August 18th, 2021
- Negrin Shines Light on the Orca-T Story in GVHD - OncLive - December 11th, 2020
- COVID-19 and the trials of treatment | News, Sports, Jobs - Escanaba Daily Press - October 16th, 2020
- NMDP/Be The Match partners with M Health Fairview and Duke University cryopreservation labs to launch Be The Match BioBank - Watauga Democrat - October 7th, 2020
- Berks County's first STEM-themed attraction opens, delights visitors young and old - Reading Eagle - October 7th, 2020
- Coronavirus Thursday update: UMN announces new stem cell ... - August 16th, 2020
- University of Minnesota launches stem cell trial against ... - August 16th, 2020
- University of Minnesota launches stem cell trial against severe COVID-19 - Minneapolis Star Tribune - August 16th, 2020
- Biotechnology Could Change the Cattle Industry. Will It Succeed? - Singularity Hub - August 16th, 2020
- Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update - Yahoo Finance - April 4th, 2020
- A word for those risking their lives amid the coronavirus crisis: Thanks - TwinCities.com-Pioneer Press - April 4th, 2020
- Coronavirus is similar to SARS and causes infection through a heart regulating enzyme: Study - International Business Times, Singapore Edition - February 4th, 2020
- Why Sangamo Therapeutics Stock Sank Today - The Motley Fool - December 13th, 2019
- Hoeven's bill supports alternative therapy for veterans with PTSD, traumatic brain injury - Ripon Advance - October 1st, 2019
- Stem-cell treatment gives two brothers a future ... - March 3rd, 2019
- The Promise of Stem Cells | Stem Cell Institute ... - August 29th, 2018
- 2018 Regenerative Medicine Minnesota Research Awards - August 17th, 2018
- FDA cracks down on stem cell clinics - CNN - August 29th, 2017
- Mayo Clinic, University of Minnesota develop 'robocop' stem cells to fight cancer - Minneapolis Star Tribune - August 24th, 2017
- Cowboy Up Ride Against Cancer - Wahpeton Daily News - August 24th, 2017
- Cargill invests in 'clean meat' start-up - KARE - August 24th, 2017
- Stem-cell clinics are using a federal website as a marketing tool for unproven treatments, U of M bioethicist says - MinnPost - July 30th, 2017
- More than 60 US clinics have sold unproven stem cell therapies for heart failure - New York Post - July 30th, 2017
- Stemonix, a stem cell research firm, wins Minnesota Cup ... - November 27th, 2016
- Minnesotas Funding of Stem Cell Research Echoes Trend ... - October 29th, 2016
- Stem cell research Experts@Minnesota - October 18th, 2016
- Stem Cell FAQs - Minnesota Regenerative Medicine - October 7th, 2016
- Minnesota invests in regenerative medicine - Health Talk - October 7th, 2016
- Minnesota to resume umbilical cord blood donations ... - September 20th, 2016
- STEM Programs - Minnesota Zoo - September 5th, 2016
- Stem Cell Treatment - Minnesota Regenerative Medicine - August 18th, 2016
- Home - Minnesota Regenerative Medicine - August 18th, 2016
- Multipotent vs. pluripotent stem cells - Pathology Student - October 19th, 2015
- 2. Bone Marrow (Hematopoietic) Stem Cells [Stem Cell ... - October 19th, 2015
- Minnesota Man With ALS Hopes Stem Cells Save His Life ... - July 2nd, 2015
- Graduate Programs - MED - Stem Cell Institute, University ... - April 26th, 2015
- Atsushi Asakura, Ph.D. - MED - Stem Cell Institute ... - March 18th, 2015
- Bioelectricity Plays Key Role in Brain Development & Repair - March 13th, 2015
- Jakub Tolar, M.D., Ph.D. - MED - Stem Cell Institute ... - February 24th, 2015
- Stem Cell Web Focus - Nature Publishing Group : science ... - February 3rd, 2015
- Family: Experimental stem-cell treatment does wonders for Gordie Howe - December 20th, 2014
- Childrens hospital gets $25M - December 16th, 2014
- Stem Cell Malaysia Blog - December 12th, 2014
- Reduction of germ cells yields more zebrafish males - December 4th, 2014
- Cardio3 BioSciences Announces the Nomination of Three Co-Principal Investigators for Its CHART-2 Phase III Clinical ... - November 28th, 2014
- Mayo Clinic Researchers Identify First Steps in Formation of Pancreatic Cancer - November 10th, 2014
- Anti-Cancer Drug Effective Against Common Stem Cell Transplant Complication - October 24th, 2014
- $25M gift prompts University pediatric hospital name change - October 16th, 2014
- Becoming a blood stem cell or bone marrow donor ... - October 3rd, 2014
- New heart built with stem cells - YouTube - September 27th, 2014
- Cancer Survivor Saved by Measles Virus Raises Funds for Expanded Trial - September 12th, 2014
- Researchers find animal model for understudied type of muscular dystrophy - August 30th, 2014
- Minnesota Stem Cell Therapy | Stem Cell Treatments - August 29th, 2014
- Stem Cell FAQs - MED - Stem Cell Institute, University of ... - August 22nd, 2014
- Home - MED - Stem Cell Institute, University of Minnesota - August 22nd, 2014
- Stem cells | Health Sciences - University of Minnesota - August 22nd, 2014